A. Heydebreck

发表

Analysis of microarray gene expression data

W. Huber, M. Vingron, A. Heydebreck, 2003 .

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors : assessment of safety and tolerability in a phase I, open-label expansion study

Manish R. Patel, K. Kelly, J. Infante, 2015 .

Bioconductor Project Bioconductor Project Working Papers Year Paper Error models for microarray intensities

W. Huber, M. Vingron, A. Heydebreck, 2013 .

Low‐level Analysis of Microarray Experiments

Martin Vingron, Wolfgang Huber, Anja von Heydebreck, 2008 .

An introduction to low-level analysis methods of DNA microarray data

W. Huber, M. Vingron, A. Heydebreck, 2005 .

Large error models for microarray intensities

W. Huber, M. Vingron, A. Heydebreck, 2005 .

Error models for microarray intensities

Martin Vingron, Wolfgang Huber, Anja von Heydebreck, 2004 .

Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.

Manish R. Patel, J. Nemunaitis, A. Heydebreck, 2016 .

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy.

K. Kelly, G. Weiss, A. Heydebreck, 2015 .

Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.

Manish R. Patel, A. Ravaud, K. Kelly, 2016 .

Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.

J. Schlom, A. Heydebreck, H. Sabzevari, 2014 .

Differential expression with the Bioconductor Project

Robert Gentleman, Anja von Heydebreck, Wolfgang Huber, 2005 .

Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases

M. Kloor, P. Schirmacher, D. Capper, 2014, Virchows Archiv.

Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.

K. Kelly, G. Weiss, A. Heydebreck, 2016 .

Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)

C. Stroh, Y. Humblet, S. Tejpar, 2008 .

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.

K. Kelly, G. Weiss, J. Infante, 2015 .

Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.

Sung Sook Lee, B. Melichar, Yoon-Koo Kang, 2016 .

Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial

L. Dirix, A. Heydebreck, M. Lippman, 2016 .

Variance stabilization applied to microarray data calibration and to the quantification of differential expression

Martin Vingron, Wolfgang Huber, Holger Sültmann, 2002, ISMB.

Phenotype with Favorable Prognosis qter Predicts a Distinct Clinical − Cell Carcinoma : Gain of 5 q 31 Prognostic Impacts of Cytogenetic Findings in Clear Cell Renal Updated

A. Poustka, T. Efferth, A. Heydebreck, 2001 .

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

J. Schlom, A. Heydebreck, R. Madan, 2017, The Lancet. Oncology.

Site-dependent differential KIT and PDGFRA expression in gastric and intestinal gastrointestinal stromal tumors

A. Heydebreck, F. Haller, B. Gunawan, 2007, Modern Pathology.

Chromosomal clustering of a human transcriptome reveals regulatory background

Jan H. Vogel, Anja von Heydebreck, Antje Purmann, 2005, BMC Bioinformatics.

Identification and Classification of Differentially Expressed Genes in Renal Cell Carcinoma by Expression Profiling on a Global Human 31 , 500-Element cDNA Array

M Vingron, A. Poustka, S. Haas, 2001 .

Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array.

A. Poustka, S. Haas, W. Huber, 2001, Genome research.

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.

K. Kelly, J. Edenfield, A. Heydebreck, 2017, The Lancet. Oncology.

Differential gene expression

A. Heydebreck, Anja Von Heydebreck, A. V. Heydebreck, 2010 .

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

K. Kelly, A. Heydebreck, J. Grewal, 2019, JAMA oncology.

3110 Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: A phase IB trial

J. Nemunaitis, A. Heydebreck, J. Gulley, 2015 .

Identifying splits with clear separation: a new class discovery method for gene expression data

Martin Vingron, Wolfgang Huber, Anja von Heydebreck, 2001, ISMB.

Elucidation of the anti-aging effects of ectoine using cdna microarray analysis and signaling pathway evaluation

S. Anzali, A. Heydebreck, T. Herget, 2010 .

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.

A. Ravaud, K. Kelly, T. Stinchcombe, 2016 .

Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis.

A. Poustka, T. Efferth, A. Heydebreck, 2001, Cancer research.

3090 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or recurrent non-small-cell lung cancer progressing after platinum-based chemotherapy: A phase Ib trial

K. Kelly, A. Heydebreck, W. Edenfield, 2015 .

Type 2 from Type 1 Tumors Cell Carcinomas : Evidence for a Cytogenetic Evolution of Cytogenetic and Morphologic Typing of 58 Papillary Renal

A. Heydebreck, G. Jakse, B. Gunawan, 2003 .

Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial : safety, clinical activity, and PD-L1 expression

C. Redfern, K. Kelly, A. Heydebreck, 2016 .

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

J. Schlom, A. Heydebreck, R. Madan, 2017, The Lancet. Oncology.

Analysis of Differential Gene Expression Studies

D. Scholtens, A. von Heydebreck, D. Scholtens, 2005 .

Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.

Yoon-Koo Kang, H. Safran, J. Infante, 2016 .

Avelumab (MSB0010718C), an anti-PD-L1 antibody, as a third-line treatment in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib JAVELIN Solid Tumor trial.

H. Safran, A. Heydebreck, A. Lockhart, 2016 .

9002 ORAL Round Robin Test to Evaluate the Reproducibility of a Therapeutically Relevant Immunohistochemical Score for the Categorization of Non-Small Cell Lung Cancer (NSCLC) Into Tumours With High and Low Epidermal Growth Factor Receptor (EGFR) Expression

Keith M. Kerr, Reinhard Büttner, A. Von Heydebreck, 2011 .

Expression with the Bioconductor Project

Robert Gentleman, Wolfgang Huber, Anja von Heydebreck, 2004 .